Bohlscheid A, Nuss D, Lieser S, Busch H-P
Zentrum für Radiologie, Sonografie und Nuklearmedizin, Krankenhaus der Barmherzigen Brüder Trier, Nordallee 1, Trier.
Rofo. 2008 Apr;180(4):302-9. doi: 10.1055/s-2008-1027228.
Assessment of fat-suppressing diffusion imaging as a tool for tumor search in primary oncological staging and follow-up after treatment.
The DWIBS sequence (DWIBS: Diffusion-Weighted Whole-Body Imaging with Background Body Signal Suppression) developed by Taro Takahara et al. was implemented in oncological MRI protocols. After measurement of 8 volunteers with a whole-body protocol, 47 whole-body scans were performed on 38 oncological patients. 70 exams were performed on 62 tumor patients with organ-specific protocols using parallel imaging. A total of 64 patients showed neoplastic lesions in the non-diffusion sequences. These lesions were evaluated in terms of visibility and signal intensity in DWIBS imaging. Non-malignant changes which showed high signal intensity in diffusion imaging were recorded in all examinations.
113 of the 125 DWIBS examinations were judged as technically good. Diffusion imaging showed bright signal in the malignant lesions of 58 of the 64 patients. The tumors of 6 patients showed only moderately bright signal or were not discernible at all. Although partly performed with free breathing of the patients and limited spatial resolution of the sequence, lesions with sizes close to voxel-size were able to be visualized. Some of the patients were seen in follow-up examinations and showed signal decrease of their lesions in case of therapy response and signal increase in recurrent disease.
Introduction of diffusion-weighted imaging provides a new independent parameter in oncological scanning. DWIBS meets the requirements of a fast, robust technique. Homogeneous fat suppression allows the use of maximum intensity projections which may visualize the spread of the disease at first glance. Most of the tumor entities examined in this study showed a bright signal in DWI. Exceptions were some osteoplastic metastases and hemorrhaged lesions. Although sensitive, visual evaluation of signal intensity alone showed limited specificity. Detection of lesions in physiological hyperintense structures may be difficult. DWIBS imaging seems to be a sensitive tool in the search for lymphomas and gastrointestinal tumors.
评估脂肪抑制扩散成像作为原发性肿瘤分期及治疗后随访中肿瘤筛查工具的价值。
采用Taro Takahara等人开发的DWIBS序列(DWIBS:背景体部信号抑制的扩散加权全身成像)用于肿瘤MRI检查方案。对8名志愿者进行全身检查后,对38例肿瘤患者进行了47次全身扫描。使用并行成像技术对62例肿瘤患者进行了70次器官特异性检查。共有64例患者在非扩散序列中显示有肿瘤性病变。对这些病变在DWIBS成像中的可见性和信号强度进行评估。在所有检查中均记录了在扩散成像中表现为高信号强度的非恶性改变。
125次DWIBS检查中有113次判定技术良好。扩散成像显示64例患者中58例的恶性病变呈高信号。6例患者的肿瘤仅显示中等亮度信号或根本无法辨认。尽管部分检查是在患者自由呼吸状态下进行且序列空间分辨率有限,但接近体素大小的病变仍可被观察到。部分患者接受了随访检查,治疗有效时病变信号降低,疾病复发时信号升高。
扩散加权成像的引入为肿瘤扫描提供了一个新的独立参数。DWIBS符合快速、可靠技术的要求。均匀的脂肪抑制允许使用最大强度投影,可一眼观察到疾病的扩散情况。本研究中检查的大多数肿瘤实体在DWI中显示高信号。骨样转移瘤和出血性病变为例外。尽管敏感,但仅通过视觉评估信号强度其特异性有限。在生理性高信号结构中检测病变可能困难。DWIBS成像似乎是寻找淋巴瘤和胃肠道肿瘤的敏感工具。